首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Efficacy and Safety of Acupuncture-Moxibustion Therapy on Chemotherapy-Induced Leukopenia: A Systematic Review and Meta-Analysis
【24h】

Efficacy and Safety of Acupuncture-Moxibustion Therapy on Chemotherapy-Induced Leukopenia: A Systematic Review and Meta-Analysis

机译:针灸治疗化疗诱导白细胞减少症的疗效和安全性:系统评价和荟萃分析

获取原文
           

摘要

Background. Acupuncture-moxibustion therapy (AMT), as an integral part of complementary and alternative medicine, has been used for centuries in treatment of numerous diseases. Nevertheless, there is no available supportive evidence on the efficacy and safety of acupuncture-moxibustion therapy in patients with chemotherapy-induced leukopenia (CIL). The purpose of this study is to evaluate the efficacy and safety of acupuncture-moxibustion therapy in treating chemotherapy-induced leukopenia. Methods. Relevant studies were searched in nine databases up to September 19, 2020. Two reviewers independently screened the studies for eligibility, extracted data, and assessed the methodological quality of selected studies. Meta-analysis of the pooled mean difference (MD) and risk ratio (RR) with their respective 95% confidence intervals (CI) were calculated. Results. 17 studies (1206 patients) were included, and the overall quality of the included studies was moderate. In comparison with medical therapy, AMT has a better clinical efficacy for CIL (RR, 1.24; 95% CI, 1.17-1.32; P0.00001) and presents advantages in increasing leukocyte count (MD, 1.10; 95% CI, 0.67–1.53; P0.00001). Also, the statistical results show that AMT performs better in improving the CIL patients’ Karnofsky performance score (MD, 5.92; 95% CI, 3.03–8.81; P0.00001). Conclusion. This systematic review and meta-analysis provides updated evidence that AMT is a safe and effective alternative for the patients who suffered from CIL.
机译:背景。针灸艾灸治疗(AMT)作为互补和替代医学的组成部分,已用于几个世纪以来治疗众多疾病。尽管如此,没有有关于灸治疗的疗效诱导的白细胞减去患者(CIL)患者的疗效和安全性的可用证据。本研究的目的是评估针灸治疗治疗化疗诱导的白细胞减少症的疗效和安全性。方法。在2020年9月19日的九个数据库中搜索了相关研究。两位审稿人独立筛选了资格,提取数据的研究,并评估了所选研究的方法论质量。计算汇总平均差(MD)和风险比(RR)的荟萃分析,其各自的95%置信区间(CI)。结果。 17项研究(1206名患者)包括在内,所纳入研究的整体质量中等。与医疗疗法相比,AMT对CIL(RR,1.24; 95%CI,1.17-1.32; P <0.00001)具有更好的临床疗效,并提高白细胞计数(MD,1.10; 95%CI,0.67-1.53 ; p <0.00001)。此外,统计结果表明,AMT在改善CIL患者的Karnofsky性能评分方面表现更好(MD,5.92; 95%CI,3.03-8.81; P <0.00001)。结论。这种系统审查和META分析提供了更新的证据,即AMT是患有CIL的患者的安全有效的替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号